Literature DB >> 20373456

Primary liver transplantation for autoimmune hepatitis: a comparative analysis of the European Liver Transplant Registry.

Christoph Schramm1, Michael Bubenheim, René Adam, Vincent Karam, John Buckels, John G O'Grady, Neville Jamieson, Stephen Pollard, Peter Neuhaus, Michael M Manns, Robert Porte, Denis Castaing, Andreas Paul, Oscar Traynor, James Garden, Styrbjörn Friman, Bo-Goran Ericzon, Lutz Fischer, Stefan Vitko, Marek Krawczyk, Herold J Metselaar, Aksel Foss, Murat Kilic, Keith Rolles, Patrizia Burra, Xavier Rogiers, Ansgar W Lohse.   

Abstract

The principal aim of this study was to compare the probability of and potential risk factors for death and graft loss after primary adult and pediatric liver transplantation in patients undergoing transplantation for autoimmune hepatitis (AIH) to those in patients undergoing transplantation for primary biliary cirrhosis (PBC; used as the reference group) or alcoholic cirrhosis (used as an example of a nonautoimmune liver disease). The 5-year survival of patients undergoing transplantation for AIH (n = 827) was 0.73 [95% confidence interval (CI) = 0.67-0.77]. This was similar to that of patients undergoing transplantation for alcoholic cirrhosis (0.74, 95% CI = 0.72-0.76, n = 6424) but significantly worse than that of patients undergoing transplantation for PBC (0.83, 95% CI = 0.80-0.85, n = 1588). Fatal infectious complications occurred at an increased rate in patients with AIH (hazard ratio = 1.8, P = 0.002 with PBC as the reference). The outcome of pediatric AIH patients was similar to that of adult patients undergoing transplantation up to the age of 50 years. However, the survival of AIH patients undergoing transplantation beyond the age of 50 years (0.61 at 5 years, 95% CI = 0.51-0.70) was significantly reduced in comparison with the survival of young adult AIH patients (0.78 at 18-34 years, 95% CI = 0.70-0.86) and in comparison with the survival of patients of the same age group with PBC or alcoholic cirrhosis. In conclusion, age significantly affects patient survival after liver transplantation for AIH. The increased risk of dying of infectious complications in the early postoperative period, especially above the age of 50 years, should be acknowledged in the management of AIH patients with advanced-stage liver disease who are listed for liver transplantation. It should be noted that not all risk factors relevant to patient and graft survival could be analyzed with the European Liver Transplant Registry database. (c) 2010 AASLD.

Entities:  

Mesh:

Year:  2010        PMID: 20373456     DOI: 10.1002/lt.22018

Source DB:  PubMed          Journal:  Liver Transpl        ISSN: 1527-6465            Impact factor:   5.799


  15 in total

Review 1.  Autoimmune hepatitis: a review.

Authors:  Andrea A Gossard; Keith D Lindor
Journal:  J Gastroenterol       Date:  2012-04-17       Impact factor: 7.527

2.  [Autoimmune liver diseases].

Authors:  N Pannicke; C Schramm; A W Lohse
Journal:  Internist (Berl)       Date:  2012-08       Impact factor: 0.743

Review 3.  Creating an effective clinical registry for rare diseases.

Authors:  Hedwig Ma D'Agnolo; Wietske Kievit; Raul J Andrade; Tom Hemming Karlsen; Heiner Wedemeyer; Joost Ph Drenth
Journal:  United European Gastroenterol J       Date:  2015-11-13       Impact factor: 4.623

4.  Outcomes in children who underwent transplantation for autoimmune hepatitis.

Authors:  Steven R Martin; Fernando Alvarez; Ravinder Anand; Changhong Song; Wanrong Yin
Journal:  Liver Transpl       Date:  2011-04       Impact factor: 5.799

Review 5.  Autoimmune hepatitis.

Authors:  Farhad Sahebjam; John M Vierling
Journal:  Front Med       Date:  2015-03-06       Impact factor: 4.592

Review 6.  Autoantibody-negative autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2011-12-21       Impact factor: 3.199

Review 7.  Current concepts in the diagnosis and management of autoimmune hepatitis.

Authors:  Stephen Kriese; Michael A Heneghan
Journal:  Frontline Gastroenterol       Date:  2012-11-12

8.  Living donor and deceased donor liver transplantation for autoimmune and cholestatic liver diseases--an analysis of the UNOS database.

Authors:  Randeep Kashyap; Saman Safadjou; Rui Chen; Parvez Mantry; Rajeev Sharma; Vrishali Patil; Manoj Maloo; Charlotte Ryan; Carlos Marroquin; Christopher Barry; Gopal Ramaraju; Benedict Maliakkal; Mark Orloff
Journal:  J Gastrointest Surg       Date:  2010-07-09       Impact factor: 3.452

9.  Macroporous Dual-compartment Hydrogels for Minimally Invasive Transplantation of Primary Human Hepatocytes.

Authors:  Nailah Seale; Suvasini Ramaswamy; Yu-Ru Shih; Inder Verma; Shyni Varghese
Journal:  Transplantation       Date:  2018-09       Impact factor: 4.939

10.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.